During the last session, Plus Therapeutics Inc (NASDAQ:PSTV)’s traded shares were 0.49 million, with the beta value of the company hitting 0.96. At the end of the trading day, the stock’s price was $0.66, reflecting an intraday loss of -1.95% or -$0.01. The 52-week high for the PSTV share is $2.67, that puts it down -304.55 from that peak though still a striking 63.64% gain since the share price plummeted to a 52-week low of $0.24. The company’s market capitalization is $11.20M, and the average intraday trading volume over the past 10 days was 2.74 million shares, and the average trade volume was 16.24 million shares over the past three months.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
Plus Therapeutics Inc (PSTV) registered a -1.95% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.95% in intraday trading to $0.66, hitting a weekly high. The stock’s 5-day price performance is -16.33%, and it has moved by 28.88% in 30 days. Based on these gigs, the overall price performance for the year is -62.37%. The short interest in Plus Therapeutics Inc (NASDAQ:PSTV) is 1.25 million shares and it means that shorts have 0.03 day(s) to cover.
Plus Therapeutics Inc (PSTV) estimates and forecasts
In the rating firms’ projections, revenue will decrease -16.51% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.11M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.14M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.68M and 1.28M respectively. In this case, analysts expect current quarter sales to shrink by -33.66% and then drop by -11.06% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.51%. While earnings are projected to return 60.68% in 2025, the next five years will return 49.80% per annum.
PSTV Dividends
Plus Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Plus Therapeutics Inc insiders own 6.07% of total outstanding shares while institutional holders control 11.43%, with the float percentage being 12.17%.
Also, the Mutual Funds coming in first place with the largest holdings of Plus Therapeutics Inc (PSTV) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Feb 28, 2025 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 34.22 shares. This amounts to just over 0.20 percent of the company’s overall shares, with a $22533.0 market value. The same data shows that the other fund manager holds slightly less at 32.54, or about 0.19% of the stock, which is worth about $21431.0.
